Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsNeighborhood RI Exdensur Coverage Policy | OpenPay…
    Ask Trek AI about this page
    CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

    Exdensur (depemokimab-ulaa) Coverage Policy

    Customize your policy alerts

    Sign up for all Neighborhood Health Plan of Rhode Island policy alerts

    Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization, medical necessity, dosing, renewal, and billing requirements for subcutaneous Exdensur used for severe eosinophilic asthma and listed pulmonary eosinophilic conditions across Medicaid pharmacy and Medicaid, Commercial, and Medicare medical scopes.

    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyExdensur (depemokimab-ulaa) Coverage Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 1, 2026
    Last ReviewMay 12, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing inadequate response, intolerance, or contraindication to both Fasenra and Nucala before requesting Exdensur.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 moInitial authorization period
    12 moRenewal interval
    100 mg/6 moMaximum dose
    12+Minimum age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    150/µL
    Eosinophil threshold
    J2361Billing code

    Coverage Criteria

    Continuation Therapy

    Renewal coverage may be granted when ALL of the following are met:

    Continuation therapy requirements

    • The member was previously approved for Exdensur through the plan's prior authorization process.

      Members not previously approved through the plan require initial evaluation review.

    • Clinical benefit

      • There has been a decrease in systemic corticosteroid use.
      • There has been a decrease in hospitalizations.
      • There has been a decrease in emergency room visits.
      • There has been a decrease in unscheduled visits to a healthcare provider.
      • There has been improvement from baseline in FEV1.
    • If the member has severe eosinophilic asthma, the member is currently treated with Exdensur within the past 90 days and is compliant with asthma control therapy, such as ICS, ICS/LABA, LTRA, LAMA, or theophylline.Treatment within the past 90 days
    • The member will not use Exdensur in combination with another immunomodulatory agent, including TNF inhibitors, JAK inhibitors, or IL-4 inhibitors.
    • The member does not have an FDA-labeled contraindication to Exdensur.

    Concurrent immunomodulatory therapy is excluded: Exdensur may not be used in combination with another immunomodulatory agent, including a TNF inhibitor, JAK inhibitor, or IL-4 inhibitor.

    FDA-labeled contraindication exclusion: Exdensur is not covered when the member has any FDA-labeled contraindication to the requested agent.

    Initial Approval Criteria

    Initial Approval Criteria

    Coverage will be provided when ALL of the following are met:

    Initial approval requirements

    • The member is 12 years of age or older.Age >= 12
    • Exdensur is prescribed by, or in consultation with, a pulmonologist or allergist/immunologist.
    • The member has a diagnosis of severe eosinophilic asthma.
    • The member has a baseline blood eosinophil count of 150 cells/microliter or higher while receiving high-dose inhaled corticosteroids or daily oral corticosteroids within the last 6 weeks.>= 150 cells/microliter within the last 6 weeks

    Renewal Criteria

    Renewal Criteria

    Authorization of 12 months may be granted when ALL of the following are met:

    Exdensur renewal requirements

    • The member was previously approved for Exdensur through the plan's prior authorization process.

      Members not previously approved through the plan require initial evaluation review.

    • Clinical benefit

      • There has been a decrease in systemic corticosteroid use.
      • There has been a decrease in hospitalizations.
      • There has been a decrease in emergency room visits.

    Required Prior Therapy

    StepRequired prior therapy or clinical exclusionDocumentation required
    1Document inadequate treatment response or intolerance to both Fasenra and Nucala, or a contraindication to both therapies, before Exdensur approval.If there was prior failure with Fasenra, Nucala, or Cinqair, provide clinical rationale explaining why the failure is not expected to occur with Exdensur.

    Dose and Frequency Limits

    Quantity Limits
    MedicationExdensur (depemokimab-ulaa)
    Maximum dose100 mg
    FrequencyEvery 6 months

    Billing and Clinical Coding

    Covered HCPCS CodesHCPCSCovered
    J2361Injection, depemokimab-ulaa, 1 mg
    Covered NDC CodesNDCCovered
    00173-0927-xxExdensur 100 mg/mL single-dose, prefilled pen or syringe
    Covered Diagnosis CodesICD-10Covered
    J45.50Severe persistent asthma, uncomplicated
    J82.81Chronic eosinophilic pneumonia
    J82.82Acute eosinophilic pneumonia
    J82.83Eosinophilic asthma
    J82.89Other pulmonary eosinophilia, not elsewhere classified
    Baseline Blood Eosinophil Count
    Minimum count150 cells/microliter or higher
    TimingWithin the last 6 weeks, prior to therapy with the requested agent
    Corticosteroid conditionsWhile on high-dose inhaled corticosteroids or daily oral corticosteroids
    Optimized Controller Therapy
    Adherence periodAt least 3 months
    Required inhaled therapyHigh-dose inhaled corticosteroid at an optimized dose

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization and Authorization Duration

    Prior authorization is required. Initial approval is provided for 12 months. Renewal may be authorized for additional 12-month intervals when renewal criteria are met.

    • Initial authorization duration: 12 months
    • Renewal interval: every 12 months
    Step Therapy

    Prior Anti-IL-5 Biologic Therapy

    Before Exdensur approval, document an inadequate treatment response or intolerance to both Fasenra and Nucala, or a contraindication to both agents. If the member previously failed an anti-IL-5 or IL-5 receptor therapy, including Fasenra, Nucala, or Cinqair, provide the clinical rationale explaining why failure is not expected with Exdensur.

    • Required prior agents: Fasenra and Nucala
    • Document inadequate response, intolerance, or contraindication to both agents

    Policy Background

    Exdensur (depemokimab-ulaa) is a subcutaneous biologic used for severe eosinophilic asthma. This policy addresses patients 12 years of age or older who have elevated baseline blood eosinophils despite high-dose inhaled corticosteroid-based controller therapy and persistent uncontrolled asthma.

    Clinical Definitions

    Severe Asthma
    Daily symptomsSymptoms throughout the day
    Nighttime awakeningsOften 7 times per week
    Short-acting beta-agonist useSeveral times per day for symptom control
    Activity limitationExtremely limited normal activities
    Lung functionFEV1 below 60% predicted
    ExacerbationsExacerbations requiring oral systemic corticosteroids are generally more frequent and intense relative to moderate asthma

    Administration Site and Method

    Note

    Administer by approved subcutaneous injection sites

    In the office setting, administer Exdensur subcutaneously by injection into the upper arm, thigh, or abdomen. Avoid the area within 2 inches (5 cm) around the navel.

    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicyExdensur (depemokimab-ulaa) Coverage Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 1, 2026
    Last ReviewMay 12, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing inadequate response, intolerance, or contraindication to both Fasenra and Nucala before requesting Exdensur.
    SourceLink
    On This Page
    Coverage CriteriaInitial Approval CriteriaRenewal CriteriaRequired Prior TherapyDose and Frequency LimitsBilling and Clinical CodingAuthorization and Documentation RequirementsPolicy BackgroundClinical DefinitionsAdministration Site and Method
  1. Optimized controller therapy for at least 3 months

    • The member is adherent to high-dose inhaled corticosteroid therapy at an optimized dose.
    • The member is adherent to an additional controller medication at an optimized dose, such as a long-acting beta2-agonist, long-acting muscarinic antagonist, or leukotriene modifier.
  2. ONE of: uncontrolled asthma evidence

    • Two or more asthma exacerbations requiring systemic corticosteroids.>= 2 in the past 12 months
    • At least one asthma exacerbation requiring hospitalization or an emergency medical care visit.>= 1 in the past 12 months
  3. The member will continue asthma control therapy in combination with Exdensur.
  4. Prior Fasenra or Nucala requirement

    • Documentation shows an inadequate treatment response or intolerance to Fasenra.
    • Documentation shows an inadequate treatment response or intolerance to Nucala.
    • The member has a contraindication to both Fasenra and Nucala.
  5. If the member has previously failed an anti-IL-5 or IL-5 receptor therapy, including Fasenra, Nucala, or Cinqair, documentation provides clinical rationale explaining why failure is not expected with Exdensur.
  6. Baseline measurements are documented for at least one of the following: systemic corticosteroid use; inhaled corticosteroid use; number of hospitalizations, emergency room visits, or unscheduled healthcare visits due to the condition; or FEV1.At least 1 baseline measure
  7. The member will not use Exdensur in combination with another immunomodulatory agent, including TNF inhibitors, JAK inhibitors, or IL-4 inhibitors.
  8. The member does not have an FDA-labeled contraindication to Exdensur.
  9. There has been a decrease in unscheduled visits to a healthcare provider.
  10. There has been improvement from baseline in FEV1.
  11. If the member has a diagnosis of severe eosinophilic asthma, the member is currently treated within the past 90 days and is compliant with asthma control therapy, such as inhaled corticosteroids, ICS/LABA, leukotriene receptor antagonist, long-acting muscarinic antagonist, or theophylline.Treatment within the past 90 days
  12. The member will not use Exdensur in combination with another immunomodulatory agent, including TNF inhibitors, JAK inhibitors, or IL-4 inhibitors.
  13. The member does not have an FDA-labeled contraindication to Exdensur.
  14. Additional controller
    An additional controller medication at an optimized dose, such as a long-acting beta2-agonist, long-acting muscarinic antagonist, or leukotriene modifier
    Oral corticosteroidsTreatment may be with or without oral corticosteroids
    Uncontrolled Asthma Exacerbations
    Required historyUncontrolled asthma while on asthma control therapy
    Exacerbation alternative 1Two or more asthma exacerbations requiring systemic corticosteroids in the past 12 months
    Exacerbation alternative 2At least one asthma exacerbation requiring hospitalization or an emergency medical care visit in the past 12 months
    Renewal Treatment Compliance
    Recent treatmentCurrently treated with Exdensur within the past 90 days
    Asthma control therapyMust remain compliant with asthma control therapy when the member has severe eosinophilic asthma
    Examples of control therapyInhaled corticosteroids, ICS/long-acting beta-2 agonist, leukotriene receptor antagonist, long-acting muscarinic antagonist, or theophylline
  15. For prior failure with Fasenra, Nucala, or Cinqair, document why Exdensur is expected to be effective
  16. Documentation Required

    Initial Clinical Documentation

    Submit initial clinical documentation confirming that the member is at least 12 years old and has severe eosinophilic asthma. Documentation must identify the prescribing pulmonologist or allergist/immunologist, provide the baseline blood eosinophil count, and show the required corticosteroid context.

    • Member is 12 years of age or older
    • Diagnosis: severe eosinophilic asthma
    • Exdensur prescribed by, or prescribed in consultation with, a pulmonologist or allergist/immunologist
    • Baseline blood eosinophil count of at least 150 cells/microliter while receiving high-dose inhaled corticosteroids or daily oral corticosteroids within the prior 6 weeks
    • Member is adherent to optimized high-dose inhaled corticosteroid and an additional controller medication for at least 3 months, with or without oral corticosteroids
    Documentation Required

    Prior Therapy and Baseline Measures

    Document uncontrolled asthma despite optimized asthma control therapy and include baseline measures for evaluating Exdensur response. The baseline record must include at least one specified disease-status measure and the required history of exacerbations or acute care use.

    • Within the prior 12 months, document either at least 2 exacerbations requiring systemic corticosteroids or at least 1 exacerbation requiring hospitalization or emergency medical care
    • Baseline measure: systemic corticosteroid use, inhaled corticosteroid use, hospitalizations/ER or unscheduled visits, or FEV1
    • Document the member's response, intolerance, or contraindication to Fasenra and Nucala and the rationale for selecting Exdensur
    • Member must continue asthma control therapy in combination with Exdensur, such as ICS, ICS/LABA, LTRA, LAMA, or theophylline
    Documentation Required

    Renewal Response Documentation

    For renewal, document clinical benefit from Exdensur compared with baseline. Benefit may be demonstrated by reduced corticosteroid use or reduced acute-care utilization, or by improved lung function.

    • Decrease in systemic corticosteroid use
    • Decrease in hospitalizations
    • Decrease in ER visits
    • Decrease in unscheduled visits to a healthcare provider
    • Improvement from baseline in FEV1
    Denial Risk

    Initial Clinical Criteria Not Met

    Initial coverage may be denied when the member does not meet all initial clinical requirements. This includes age, specialist prescribing, severe eosinophilic asthma, eosinophil and corticosteroid documentation, optimized controller therapy, uncontrolled-asthma history, continuation of asthma control therapy, and the required prior-biologic history or clinical rationale.

    • Member is younger than 12 years
    • Exdensur is not prescribed by or in consultation with a pulmonologist or allergist/immunologist
    • Severe eosinophilic asthma or the required baseline eosinophil count is not documented
    • Required high-dose inhaled corticosteroid, additional controller therapy, adherence, or corticosteroid documentation is absent
    • Required exacerbation, hospitalization, or emergency-care history is not demonstrated
    • Continuation of asthma control therapy is not documented
    • Required baseline clinical measurements are not provided
    Denial Risk

    Required Prior Biologic History Missing

    Initial coverage may be denied when documentation does not establish inadequate response or intolerance to both Fasenra and Nucala, or a contraindication to both agents. When prior anti-IL-5 or IL-5 receptor therapy failed, the submission must also explain why Exdensur is not expected to fail.

    • Missing documentation of inadequate response to both Fasenra and Nucala
    • Missing documentation of intolerance to both Fasenra and Nucala
    • Missing contraindication documentation for both Fasenra and Nucala
    • No clinical rationale provided after documented failure with Fasenra, Nucala, or Cinqair
    Denial Risk

    Contraindication or Prohibited Combination

    Do not use Exdensur concurrently with another immunomodulatory agent. Coverage may also be denied when the member has any FDA-labeled contraindication to Exdensur.

    • Prohibited combination includes another immunomodulatory agent such as a TNF inhibitor, JAK inhibitor, or IL-4 inhibitor
    • Confirm the member has no FDA-labeled contraindication to Exdensur
    Denial Risk

    Renewal Response or Continuity Criteria Not Met

    Renewal may be denied unless the member was previously approved through the plan's Prior Authorization process, has documented clinical benefit, remains compliant with required asthma control therapy when applicable, and continues to satisfy the safety requirements.

    • Member was not previously approved through the plan's Prior Authorization process; members without prior approval require initial evaluation
    • No documented decrease in systemic corticosteroid use, hospitalizations, ER visits, or unscheduled visits, and no improvement in FEV1 from baseline
    • For severe eosinophilic asthma, the member is not currently treated within the past 90 days or is not compliant with asthma control therapy
    • Requested agent will be used with another immunomodulatory agent
    • Member has an FDA-labeled contraindication to Exdensur